Epoxide Hydrolase

Cat. No.

A16887

CAS No.

948304-40-3

UC-1728

Synonyms: t-TUCB

UC-1728, also known as t-TUCB, is a soluble epoxide hydrolase inhibitor.

Cat. No.

A19412

CAS No.

913548-29-5

AR-9281

Synonyms: APAU

AR9281 is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH), with potential for the treatment of hypertension and type 2 diabetes.

Cat. No.

A20368

CAS No.

1222780-33-7

TPPU

TTPU is a soluble epoxide hydrolase (sEH) inhibitor with IC50 values of 37 and 3.7 nM for monkey and human sEH, respectively.

Cat. No.

A20696

CAS No.

1142090-23-0

GSK2256294A

Synonyms: GSK 2256294

GSK2256294A is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH.

Cat. No.

A22346

CAS No.

479413-70-2

AUDA

AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.

Cat. No.

A22690

CAS No.

402939-18-8

1-Cyclohexyl-3-dodecyl urea

Synonyms: CDU; N-Cyclohexyl-N-dodecyl urea; NCND

1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) is a highly selective soluble epoxide hydrolase (sEH) inhibitor.

Cat. No.

A26395

CAS No.

2847838-67-7

sEH/HDAC6-IN-1

sEH/HDAC6-IN-1 is a selective, orally active dual inhibitor of soluble epoxide hydrolase (sEH) and histone deacetylase 6 (HDAC6), exhibiting IC50 values of 2 nM for human sEH, 0.72 nM for murine sEH, and 5 nM for HDAC6. This compound demonstrates notable analgesic and anti-inflammatory properties, making it a valuable tool for research into pain management and inflammatory disorders. The ability to simultaneously target these two enzymes provides insights into their roles in various biological processes.

Cat. No.

A26403

CAS No.

3009011-58-6

sEH/HDAC6-IN-2

sEH/HDAC6-IN-2 is a potent dual inhibitor targeting soluble epoxide hydrolase (sEH) and histone deacetylase 6 (HDAC6), demonstrating IC50 values of 0.9 nM for human sEH, 46.8 nM for mouse sEH, and 8 nM for HDAC6. This compound is significant for investigating inflammatory pain mechanisms and related biological pathways, potentially aiding in the development of novel analgesics. Its dual activity positions it as a valuable tool in research focused on neuroinflammation and pain management.

Cat. No.

A39948

CAS No.

479413-68-8

CUDA

CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), exhibiting IC50 values of 11.1 nM for mouse sEH and 112 nM for human sEH. By selectively enhancing peroxisome proliferator-activated receptor (PPAR) alpha activity, CUDA can significantly influence metabolic processes. This compound is valuable for research applications focused on cardiovascular disease and related metabolic disorders.

Cat. No.

A74585

CAS No.

1809885-32-2

EC5026

Synonyms: BPN-19186

EC5026 is a novel, orally active soluble Epoxide Hydrolase (sEH) inhibitor. It demonstrates significant efficacy in models of inflammatory and neuropathic pain, making it a valuable tool for research in pain management and related disorders. This first-in-class compound serves as an important resource for studying the modulation of pain pathways and exploring therapeutic strategies targeting sEH.

Cat. No.

A74587

CAS No.

885012-33-9

trans-AUCB

Synonyms: t-AUCB

trans-AUCB is a selective inhibitor of soluble epoxide hydrolase (sEH), demonstrating potent inhibitory activity with IC50 values of 1.3 nM for human sEH, 8 nM for mouse sEH, and 8 nM for rat sEH. This compound exhibits anti-glioma properties, making it a valuable tool for research investigating epoxide signaling pathways and potential therapeutic approaches in glioma treatment.

Cat. No.

A74588

CAS No.

2376322-12-0

SWE101

SWE101 is a potent inhibitor of soluble epoxide hydrolase (sEH), exhibiting IC50 values of 4 µM for human sEH and 2.8 µM for rat sEH. It selectively targets the sEH-P isoform without affecting the hydrolase or phosphatase activities of mouse sEH. SWE101 is valuable for research focusing on the modulation of epoxide signaling pathways and the investigation of related physiological and pathological processes.

Cat. No.

A74590

CAS No.

940954-41-6

BI-1935

BI-1935 is a potent inhibitor of soluble epoxide hydrolase (sEH), targeting the enzyme responsible for the hydrolysis of epoxyeicosatrienoic acids. This compound exhibits significant potential in modulating inflammatory and cardiovascular processes by enhancing vascular function. It serves as a valuable tool for investigating mechanisms underlying cardiovascular diseases and exploring therapeutic strategies for related conditions.

Cat. No.

A74593

CAS No.

1466-67-7

1,3-Dibenzylurea

Synonyms: N,N′-Dibenzylurea

1,3-Dibenzylurea is an inhibitor of soluble epoxide hydrolase (sEH), primarily targeting epoxide hydrolase enzymes. This compound exhibits significant biological activity as an insect growth regulator and is utilized in research focusing on metabolic pathways involving epoxides. Its role in modulating sEH activity makes it relevant for studies related to inflammation, cardiovascular health, and other physiological processes influenced by epoxides.

Cat. No.

A74594

CAS No.

340221-20-7

sEH inhibitor-7

sEH inhibitor-7 is a potent inhibitor of soluble epoxide hydrolase (sEH), exhibiting IC50 values of 0.15 μM for mouse sEH and 6.2 μM for human sEH. By targeting sEH, this compound plays a significant role in modulating the metabolism of endogenous epoxyeicosanoids, which are critical in regulating blood pressure and inflammatory responses. This reagent is valuable for research applications focused on cardiovascular health and inflammation pathways.

Cat. No.

A74595

CAS No.

2387-23-7

1,3-Dicyclohexylurea

1,3-Dicyclohexylurea (DCU) functions as a potent inhibitor of soluble epoxide hydrolase (sEH). Its oral bioavailability makes it a valuable tool in research applications aimed at exploring mechanisms of blood pressure regulation. Studies have demonstrated that the administration of 1,3-Dicyclohexylurea nanosuspension can significantly enhance systemic exposure and effectively lower blood pressure in hypertensive rat models.

Cat. No.

A74596

CAS No.

1208549-68-1

sEH inhibitor-1

sEH inhibitor-1 is a potent inhibitor of soluble epoxide hydrolase (sEH) that demonstrates IC50 values of 0.4 nM in human and 5.3 nM in murine systems. This compound effectively modulates the metabolism of epoxyeicosanoids, offering potential therapeutic implications in the regulation of inflammation, pain, and cardiovascular diseases. It serves as a valuable tool for research applications focused on sEH inhibition and its effects on various biological processes.

Cat. No.

A74597

CAS No.

1809885-55-9

(Rac)-EC5026

Synonyms: (Rac)-BPN-19186

(Rac)-EC5026 is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) with a Ki of 0.06 nM. This compound demonstrates significant biological activity relevant to neurological disorders, making it a valuable tool for investigating the pathophysiology of Parkinson's disease and dementia with Lewy Bodies (DLB). Researchers can utilize (Rac)-EC5026 to explore therapeutic strategies targeting sEH in the context of these conditions.

Cat. No.

A74600

CAS No.

1205963-04-7

sEH inhibitor-6

sEH inhibitor-6 is a potent inhibitor of soluble epoxide hydrolase (sEH), exhibiting an IC50 value of 0.5 nM. This small molecule is utilized in research studies focused on lipid metabolism and inflammatory processes, where sEH modulation plays a crucial role. The compound's ability to selectively inhibit sEH makes it a valuable tool in exploring its biological implications and potential therapeutic applications.

Cat. No.

A74603

CAS No.

74213-96-0

Thalictoside

Thalictoside is a selective inhibitor of soluble epoxide hydrolase (sEH) with an IC50 value of 20.2 µM. It demonstrates anti-osteoporotic effects through an estrogen-like mechanism, making it relevant for investigations related to bone health. Additionally, Thalictoside is useful in the study of cardiovascular and urinary diseases, offering insights into the modulation of lipid mediator signaling pathways.

Cat. No.

A74608

CAS No.

76873-99-9

Hydroxytyrosol 1-O-glucoside

Synonyms: Dopaol glucoside

Hydroxytyrosol 1-O-glucoside is a glycoside that primarily acts as an inhibitor of epoxide hydrolase 2. This compound exhibits notable antioxidant activity, making it valuable in research focused on oxidative stress and related cellular mechanisms. Its role in modulating enzymatic pathways can be leveraged in studies investigating various metabolic disorders and potential therapeutic strategies.

Cat. No.

A74609

CAS No.

1809885-35-5

sEH inhibitor-3

sEH Inhibitor-3 is a highly potent and orally active inhibitor of soluble epoxide hydrolase (sEH), exhibiting a Ki value of 0.75 nM against human sEH. This compound effectively modulates the metabolism of epoxyeicosanoids, playing a crucial role in inflammation and cardiovascular diseases. It serves as a valuable tool for research applications aimed at exploring sEH’s involvement in various biological processes and developing therapeutic strategies for related disorders.

Cat. No.

A74610

CAS No.

2890221-26-6

sEH inhibitor-14

sEH inhibitor-14 is a potent soluble Epoxide Hydrolase (sEH) inhibitor, with an IC50 value of 0.39 nM. This benzoxazolone-5-urea analogue effectively modulates epoxide metabolism, influencing pathways related to inflammation and cardiovascular function. It serves as a valuable tool in research focused on endocannabinoid signaling and the therapeutic potential of sEH inhibition in various biological systems.

Cat. No.

A74612

CAS No.

1061377-99-8

sEH-IN-1

sEH-IN-1 is a potent soluble epoxide hydrolase (sEH) inhibitor. It demonstrates significant biological activity by modulating the levels of epoxyeicosanoids, which are crucial in various physiological processes. This compound is valuable for research applications focused on sEH-mediated diseases, including hypertension, cardiovascular disease, inflammation, and diabetes, enabling insights into potential therapeutic interventions.

Cat. No.

A74613

CAS No.

2305966-67-8

sEH-IN-22

sEH-IN-22 is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 1.1 μM, derived from Rubia philippinensis. This compound demonstrates anti-inflammatory, analgesic, and blood pressure-regulating properties, making it a valuable tool in research focused on inflammation, neurological disorders, and cardiovascular diseases. Its mechanism of action and biological activity make it an important reagent for advancing studies aimed at understanding and treating these conditions.